ViroPharma Announces Results of Tender Offer for its 2.00% Convertible Senior Notes Due 2017

ViroPharma Announces Results of Tender Offer for its 2.00% Convertible Senior
                                Notes Due 2017

PR Newswire

EXTON, Pennsylvania, February 25, 2014

EXTON, Pennsylvania, February 25, 2014 /PRNewswire/ --

ViroPharma Incorporated today announced the results of its tender offer (the
"Convertible Notes Tender Offer") pursuant to which each holder of the 2.00%
Convertible Senior Notes Due 2017 (the "Convertible Notes") had the right (the
"Fundamental Change Repurchase Right") to require ViroPharma to repurchase all
of such holder's Convertible Notes, or any portion thereof that is a multiple
of $1,000 principal amount, on February 25, 2014. The Fundamental Change
Repurchase Right expired at 5:00 p.m., New York City time, on February 24,
2014 (the "Fundamental Change Expiration Time"), and was not extended.
ViroPharma has been advised by Wilmington Trust Company, the Paying Agent and
the Conversion Agent for the Convertible Notes Tender Offer, that none of the
Notes were validly surrendered for repurchase prior to the Fundamental Change
Expiration Time. 

Forward-Looking Statements

Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, ViroPharma's results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks and uncertainties detailed from time to time in
ViroPharma's filings with the SEC, including its most recent Annual Report on
Form 10-K.

SOURCE Shire plc

Contact: Contact: Jessica Mann, +44(0)1256-894-280.
 
Press spacebar to pause and continue. Press esc to stop.